Everything below concerns Fragment designation. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-04-11. Where a claim depends on a specific study, the study is described rather than over-claimed.
Outside laboratory supply channels, the peptide is sold as a research chemical, a category that carries no requirement to demonstrate purity, identity, or freedom from contamination. Because it is not an approved medicine, products labeled BPC-157 sit in a regulatory gap in many countries, and actual content may differ from the label. Sports organizations list it among prohibited substances, so its presence in an athlete's sample can produce a doping finding regardless of how the material was obtained.
BPC-157 is a synthetic peptide of fifteen amino acids, written as GEPPPGKPADDAGLV, whose sequence matches part of a larger protein identified in human gastric juice. That parent protein was described in stomach-secretion research, and the fifteen-residue fragment was named body protection compound, which gives the peptide its common label. Material used in experiments is produced by solid-phase peptide synthesis rather than extracted from tissue. The reported molecular weight is about 1419 daltons, and the chain contains several proline residues, a feature that appears in discussions of its resistance to enzymatic breakdown.
Most published findings come from rodent models, where the peptide has been examined in wound-healing, gastrointestinal-lesion, tendon, and vascular-injury preparations. A smaller number of early human studies have been reported, chiefly in inflammatory bowel conditions, but the public record is short and has not led to marketing approval in the United States or the European Union. Reviewers therefore classify the compound as investigational, and whether animal results carry over to people remains an open question rather than a settled one.
Several mechanisms have been proposed to explain the activity observed in animal models. The most frequently cited involve signaling through vascular endothelial growth factor receptor 2 and modulation of the nitric oxide system. Researchers have also described interactions with protective pathways in the gut lining. These proposed mechanisms appear in the literature as hypotheses supported by preclinical observations, not as confirmed pathways in humans. The precise way the peptide produces its reported effects, and whether those effects carry across species, remain areas of active and unresolved investigation.
BPC-157 is a synthetic pentadecapeptide, meaning it consists of fifteen amino acids joined in a single chain. Its sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, a fragment corresponding to part of a larger protein found in human gastric juice. The peptide was first described in the 1990s by researchers in Zagreb who were studying gastric protective factors. It is not a naturally circulating hormone; it is a laboratory-made fragment derived from a stomach protein. The name is an abbreviation of body protection compound, with the number referring to the fragment's position in the source protein.
Most published work on BPC-157 comes from animal experiments rather than controlled human trials. Rodent models have examined its effects on gastrointestinal lesions, tendon and ligament injury, and blood vessel formation. These studies are often small and originate from a limited number of research groups, which affects how broadly the findings can be generalized. No large randomized human trial has been reported in the peer-reviewed literature. Discussion of the compound therefore rests largely on preclinical data, and questions about its effects in people remain open rather than settled.
| Property | Value | Notes |
|---|---|---|
| Origin | Fragment of a protein found in human gastric juice | Sequence corresponds to a fifteen-residue portion of the parent protein |
| Sequence | GEPPPGKPADDAGLV | Single linear chain, fifteen amino acids |
| Reported molecular weight | About 1419 daltons | Value quoted consistently in supplier and review literature |
| Regulatory status | Not an approved human medicine in the US or EU | Handled and sold as a research chemical |
| Sports status | Listed as prohibited | Falls under non-approved-substance categories in anti-doping codes |
The sequence places several glycine and proline residues near the middle, which may influence how the chain folds in solution. The peptide is linear rather than cyclic, and it carries no disulfide bridges. Commercial material is commonly supplied as the acetate salt, although the free base and other counterion forms also appear. Because the term BPC-157 refers to a specific sequence, samples with slight sequence variants are chemically different substances. Published work generally treats the fifteen-residue sequence as the defining structure.
Physical descriptions in supplier documents and papers usually list the compound as a white to off-white powder. It dissolves readily in water and in common aqueous buffers, and solutions are often prepared fresh before an experiment. Molecular mass near 1419 daltons helps verify identity during mass spectrometry. The powder is somewhat hygroscopic, so moisture exposure can alter the measured mass of a sample. Purity is typically reported as a percentage from chromatographic analysis.
BPC-157 is a synthetic fifteen-amino-acid peptide whose sequence is GEPPPGKPADDAGLV. Its name derives from the phrase body protection compound, a term applied to a protein fraction originally detected in human gastric juice. The short peptide is not that full protein; it corresponds to a stable fragment of the larger molecule. Researchers frequently describe it as a pentadecapeptide because it contains exactly fifteen residues. Its neutral molecular mass is approximately 1419 daltons.
BPC-157 is a synthetic pentadecapeptide whose sequence is commonly given as Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It is described in the literature as a fragment of a larger protein found in human gastric juice, referred to as body protection compound. The peptide was first characterized in the early 1990s by a research group in Zagreb, Croatia. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
Supplied material is typically a lyophilized white to off-white powder. The peptide is freely soluble in water and in common aqueous buffers, which allows it to be handled as a stock solution. Because the sequence contains no cysteine, disulfide cross-linking is not a route of degradation. The absence of aromatic residues means ultraviolet absorbance at 280 nm is minimal, so quantification usually relies on peptide bond absorbance near 214 nm or on amino acid analysis.
BPC-157 is a synthetic peptide built from fifteen amino acid residues. Its sequence comes from a larger protein fragment that researchers isolated from human gastric juice and described as a body protection compound. The fragment contains glycine, glutamic acid, five prolines, lysine, alanine, two aspartic acids, leucine, and valine. The number 157 in the name refers to the position of the stretch within the parent protein. Material used in laboratories is manufactured rather than extracted from stomach fluid.
The molecule carries 15 residues, a molar mass near 1419.5 g/mol, and the formula C62H98N16O22. Its structure features a proline-rich central region, a pair of adjacent aspartic acid residues, and no cysteine. The absence of cysteine means no disulfide bonds can form, which simplifies refolding and reconstitution. Suppliers usually ship the material as a freeze-dried powder that appears white to off-white. It dissolves readily in water and in saline solutions.
Published storage guidance follows general peptide practice rather than product-specific studies. The dry powder is typically kept at minus 20 degrees Celsius, away from light and moisture. Once reconstituted, solutions are generally refrigerated and used over days to weeks, because the aqueous environment slowly promotes hydrolysis and oxidation. Long-term data on degradation rates or breakdown products are sparse. Stated shelf lives from different producers vary widely, reflecting the absence of a shared reference standard.
BPC-157 is a synthetic peptide of fifteen amino acids, written in single-letter code as GEPPPGKPADDAGLV. The sequence corresponds to a partial fragment of a protein isolated from human gastric juice, described in early reports as body protection compound. The number 157 refers to a fragment designation in that work rather than to molecular mass. Initial descriptions appeared in the early 1990s, when the fragment was reported to protect gastrointestinal tissue in animal models. Commercial material is produced by solid-phase peptide synthesis rather than extracted from biological sources.
Laboratory research on this peptide has examined a wide and heterogeneous set of endpoints, including gastric ulcer models, tendon and ligament injury, wound closure, and intestinal inflammation. Most published findings come from rodent studies, and reported effect sizes are often large relative to controls. Because the compound has been tested across many unrelated injury models, the literature is frequently described as unusually broad for a single peptide. A substantial share of this work originates from a small number of research groups, which matters when assessing how widely results have been reproduced.
== Chemically modified nucleotides == Recently, SELEX has expanded to include the use of chemically modified nucleotides. These chemically modified oligonucleotides offer many potential advantages for selected aptamers including greater stability and nuclease resistance, enhanced binding for select targets, expanded physical properties - like increased hydrophobicity, and more diverse structural conformations. The genetic alphabet, and thus possible aptamers, is also expanded using unnatural base pairs the use of these unnatural base pairs was applied to SELEX and high affinity DNA aptamers were generated.
=== Energy generation === In April 2022, Moore signed a Chesapeake Climate Action Network pledge to support legislation to get Maryland to use 100 percent carbon-free electricity by 2035 and to remove trash incineration from the state's "clean energy" classification. In March 2023, he set a goal of achieving 8.5 gigawatts of wind power generation in the state by 2031, which was later codified after he signed the POWER Act in April 2023. In August 2025, Moore criticized the Trump administration's plans to revoke federal offshore wind permits for US Wind's proposed wind farm off the coast of Ocean City, Maryland, calling it "utterly shortsighted" and noting that the project was set to bring $1 billion in investments to the state. In October 2023, Moore criticized the Maryland Public Service Commission for unanimously rejecting Aligned Data Centers's request to install 168 three-megawatt diesel generators at a data center it hoped to build in Frederick County. During the 2024 legislative session, he introduced legislation that exempts these kinds of generators from environmental review processes; after facing opposition from the Maryland League of Conservation Voters, the bill was amended to require 15% of all tax revenues collected from data center operations to go toward the state's clean energy fund. The bill passed and was signed into law by Moore.
=== International and Enterprise divisions === UPMC's International and Commercial Services Division (ICSD) actively manages UPMC's for-profit companies that seek to commercialize its expertise in health care, advanced technologies, and management skills to global markets. Its stated goal is "to advance UPMC's mission of positively transforming the way health care is provided in the U.S. and abroad, while revitalizing the economy of western Pennsylvania." UPMC International provides health care consulting and management services around the world in areas in various areas including clinical program development, facility and construction planning, clinical investigation, clinical and administrative staff training, and health information technology, and quality, safety, and Innovation. UPMC Enterprises is an innovation and commercialization arm of UPMC which has invested over $700 million in about 80 different ventures in the past twenty years. It seeks to create products and business arising from translational science and technology solutions by collaborating with entrepreneurs. In the past, it has also forged collaborations with companies such as dbMotion) and strategic and commercial product development partnerships with companies such as IBM and Alcatel-Lucent. UPMC Enterprises portfolio includes such companies as ALung, and Prodiogo Solutions.
Clotiazepam (marketed under brand name Clozan, Distensan, Trecalmo, Rize, Rizen and Veratran) is a thienodiazepine drug which is a benzodiazepine analog. The clotiazepam molecule differs from benzodiazepines in that the benzene ring has been replaced by a thiophene ring. It possesses anxiolytic, skeletal muscle relaxant, anticonvulsant, sedative properties. Stage 2 NREM sleep is significantly increased by clotiazepam.
==== Effects on spermatogenesis and fertility ==== Spermatogenesis and male fertility are dependent on FSH, LH, and high levels of testosterone within the testicles. LH does not seem to be involved in spermatogenesis outside of its role in inducing production of testosterone by the Leydig cells in the seminiferous tubules (which make up approximately 80% of the bulk of the testes), whereas this is not the case for FSH, which is importantly involved. In accordance with the fact that the testes are the source of 95% of circulating testosterone in the body, local levels of testosterone inside of the testes are extremely high, ranging from 20- to 200-fold higher than circulating concentrations. Moreover, high levels of testosterone within the testes are required for spermatogenesis, although only a small fraction (5–10%) of normal levels appears to actually be necessary for spermatogenesis. Unlike with antigonadotropic antiandrogens like CPA and GnRH analogues, it has been reported that bicalutamide monotherapy (at 50 mg/day) has very little or no effect on the ultrastructure of the testes and on spermatogenesis in men even after long-term therapy (>4 years). This may be explained by the extremely high local levels of testosterone in the testes, in that it is likely that systemic bicalutamide therapy is unable to achieve concentrations of the drug within the testes that are able to considerably block androgen signaling in this part of the body.
Sources: en.wikipedia.org
== Properties == Umami has a mild but lasting aftertaste associated with salivation and a sensation of furriness on the tongue, stimulating the throat, the roof and the back of the mouth. By itself, umami is not palatable, but it makes a great variety of foods pleasant, especially in the presence of a matching aroma. Like other basic tastes, umami is pleasant only within a relatively narrow concentration range. The optimum umami taste also depends on the amount of salt, and at the same time, low-salt foods can maintain a satisfactory taste with the appropriate amount of umami. One study showed that ratings of pleasantness, taste intensity, and ideal saltiness of low-salt soups were greater when the soup contained umami, whereas low-salt soups without umami were less pleasant. Another study demonstrated that using fish sauce as a source of umami could reduce the need for salt by 10–25% to flavor such foods as chicken broth, tomato sauce, or coconut curry while maintaining overall taste intensity. Some population groups, such as the elderly, may benefit from umami taste because their taste and smell sensitivity may be impaired by age and medication. The loss of taste and smell can contribute to poor nutrition, increasing their risk of disease. Some evidence exists to show umami not only stimulates appetite, but also may contribute to satiety.
== Treatment == The major emphasis of the treatment of JIA is helping the child or young person regain normal levels of physical and social functioning by controlling inflammation and extra-articular symptoms. Clinical remission should be the primary target for all people. Prompt recognition and management is important as early initiation of medication therapy increases the likelihood of a response to first-line treatments and low disability. Consensus treatment guidelines exist for the treatment of JIA. Optimal management of JIA requires a multidisciplinary team working to address the needs of an individual child. Optimizing physical and social functioning is accomplished using non-pharmacological strategies such as physical therapies, pain management strategies, and social supports. Medications are used to control inflammation and reduce or prevent extra-articular symptoms.Non-steroidal anti-inflammatory drugs (NSAIDs) are used for symptomatic relief of joint pain in children with JIA. Disease-modifying antirheumatic drugs (DMARDs), which inhibit specific pathways in the inflammation pathways responsible for JIA, are a primary treatment. Lifelong DMARD treatment is often required, and drug-free remission is exceedingly rare. Oligoarticular JIA (which comprises 40-50% of all JIA cases) by definition involves 4 or fewer joints in the first 6 months of the disease. After 6 months, some cases become polyarticular (involving more than 4 joints). This polyarticular subtype is associated with a lower remission rate with medical therapy.
Hypervalency is almost unknown in the 2p elements for the same reason, because the high electronegativity makes it difficult for a small nitrogen atom to be a central atom in an electron-rich three-center four-electron bond since it would tend to attract the electrons strongly to itself. Thus, despite nitrogen's position at the head of group 15 in the periodic table, its chemistry shows huge differences from that of its heavier congeners phosphorus, arsenic, antimony, and bismuth. Nitrogen may be usefully compared to its horizontal neighbours' carbon and oxygen as well as its vertical neighbours in the pnictogen column, phosphorus, arsenic, antimony, and bismuth. Although each period 2 element from lithium to oxygen shows some similarities to the period 3 element in the next group (from magnesium to chlorine; these are known as diagonal relationships), their degree drops off abruptly past the boron–silicon pair. The similarities of nitrogen to sulfur are mostly limited to sulfur nitride ring compounds when both elements are the only ones present. Nitrogen does not share the proclivity of carbon for catenation. Like carbon, nitrogen tends to form ionic or metallic compounds with metals. Nitrogen forms an extensive series of nitrides with carbon, including those with chain-, graphitic-, and fullerenic-like structures. It resembles oxygen with its high electronegativity and concomitant capability for hydrogen bonding and the ability to form coordination complexes by donating its lone pairs of electrons.
Condom Cestino was elected Grand Master, and Jose Alvarez Rivera Maldonado was elected Grand Secretary. In 1965, the Grand Lodge of Massachusetts took over the dispensation of the Caribbean Naval Lodge, which is the Masonic Naval Lodge at Guantanamo Bay Naval Base. Into the year 1967, the Masonic Service Association of the United States publication Foreign Grand Lodges Recognized By the Forty-nine Grand Lodges of the United States stated that 38 Grand Lodges in the United States were still in regular "fraternal communication" with the Grand Lodge of Cuba at Havana. From 1967 to 2007, no new Lodges were created in Cuba. In 1970, the street in front of the National Temple was officially renamed after Salvador Allende, who was not only a good friend of Fidel Castro, but also a prominent Freemason himself.
Sources: en.wikipedia.org
== Career == Henriksen found work as a muralist and as a laborer on ships. For a time, he worked in Europe. Around age 30, he found theater work as a set designer, and he received his first acting role because he built the set for a production. It was around this time that he taught himself to read. For his first role, he put the entire script on tape with the help of a friend, then learned his part and all of the others. Soon afterward, he graduated from the Actors Studio and began acting in New York City. Henriksen's first film appearance was in The Outsider in 1961, as an uncredited extra. He received his first credit in his second film, 1972's It Ain't Easy. He auditioned for the role of Leon Shermer in Dog Day Afternoon (1975), but received the smaller part of an FBI agent that kills John Cazale's character. He appeared in two more films directed by Sidney Lumet: Network (1976) and Prince of the City (1981). In a 2009 interview, Henriksen called Lumet "the kind of guy that loves New York actors, because that's where he works and that's what he knows....He would give you the job that was maybe only meant for four days, and he'd give you the run of the show because he wanted to help support young actors in New York." Henriksen had supporting roles in a variety of films, including the science-fiction film Close Encounters of the Third Kind (1977) and the horror film Damien - Omen II (1978). He also had co-starring roles in the low-budget horror film Mansion of the Doomed (1976) and the Italian-produced science fiction film The Visitor (1979).
== Other uses == Queensland University of Technology and the State Library of Queensland have been using kombucha SCOBY to produce a workable bio-textile, considered a type of vegan leather. A small international team of material and computer engineers from the UK, Italy and Greece has tested the possibility of using kombucha SCOBY to produce electronic circuit boards.
== Absorption and metabolism == NMNH has proven to be a more effective NAD+ enhancer than NMN, achieving a 5-fold increase in NAD+ levels and sustaining elevated levels for six hours while maintaining high levels for up to 24 hours. NMNH treatment leads to a similar trend in NAD+ and NADH biosynthesis as NMN treatment, implying a shared pathway. However, NMNH was shown to inhibit the endogenous synthesis of NMN by blocking the action of nicotinamide phosphoribosyl transferase (NAMPT) This inhibition suggests that NMNH may be more effective than NMN in directly stimulating NAD+ production.
Sources: en.wikipedia.org
It is not approved for human use in the United States or the European Union. Clinical material has been studied in a small number of early trials, mainly for inflammatory bowel conditions, and the compound remains investigational. Regulators treat marketed products as unapproved rather than as authorized drugs.
The peptide was named after a protein fraction found in human gastric juice, and the shorter form was called body protection compound. That phrase was shortened to the abbreviation BPC. The number 157 refers to a laboratory designation used in the original isolation work.
Its sequence corresponds to a segment of a protein present in gastric secretions, but the material supplied for research is made synthetically. No commercial product is purified from human or animal tissue. The synthetic route is used because it gives a defined chain length and a reproducible sequence.
It is a chain of fifteen amino acids, referred to as a pentadecapeptide. The sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It corresponds to a fragment of a protein found in human gastric juice.